No site-of-care requirement for BrineuraTM for BCN HMOSM (commercial) members

Brineura (cerliponase alfa), a medication covered under the medical benefit, will not be subject to a site-of-care requirement starting July 1, 2018, for BCN HMO (commercial) members, as we had previously announced.

In April, we communicated that we were adding Brineura to the site-of-care optimization program starting July 1. However, we have decided after additional review that we will not add Brineura to that program.

The document Requirements for drugs covered under the medical benefit – BCN HMO has been updated to reflect this change. However, please check that document for the authorization requirements that do pertain to Brineura and for the requirements that pertain to other drugs covered under the medical benefit for BCN HMO (commercial) members.

Posted: May 2018
Line of business: Blue Care Network